iiinova — where your digital self keeps evolving

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 17/09/2026

Could alectinib be used before surgery for ALK+ #lungcancer? In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery. It’s early research, but an interesting new direction for ALK+ treatment. #WCLC26 #ALKPositive #LCSM

020

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 12/09/2026

The 5th ALK Positive Lung Cancer UK National Conference is coming up on 25–27 September. Expert speakers will cover clinical trials, ALK research, survivorship, side effects, pharmacy advice and more, with plenty of time for questions and peer support. #LCSM www.alkpositive.org.uk/national-con...

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 11/09/2026

Our 2025 Impact Report looks back at everything our ALK+ #lungcancer community helped make possible, from our biggest national conference yet and growing regional meet-ups to new support, trusted information and stronger advocacy for people with ALK+. www.alkpositive.org.uk/_files/ugd/3... #LCSM

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 09/09/2026

Scotland has confirmed routine NHS access to lorlatinib after previous ALK+ lung cancer treatment. It had been available on an interim basis since 2020. Following reassessment and further evidence, that access is now routine. #ALKPositive #LungCancer #LCSM

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 07/09/2026

It’s #WorldRadiotherapyAwarenessDay. Radiotherapy can also play an important role in ALK+ #lungcancer. It may be used to treat cancer in the brain or other parts of the body, control one or a small number of areas that have started growing, or relieve symptoms. #LCSM

072

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 03/09/2026

New research is helping us understand why ALK targeted treatments can stop working. In 148 people with ALK+ #lungcancer, researchers identified changes in the RAS pathway as one possible route of resistance. An important clue for future research. #ALKPositive #LungCancer #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 30/08/2026

One week today, Jade will be taking on the Tour de 4 Red Route. 🚲 She’s doing it to challenge perceptions of what life with stage 4 #lungcancer can look like, raise awareness that anyone with lungs can get lung cancer, and raise funds for ALK+ UK. #LCSM gofund.me/990f07ef3

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 29/08/2026

1 month to go before our 5th ALK+ #LungCancer National Conference. It’s free for people in the UK living with ALK+ plus 1. Accommodation is included & reasonable travel expenses. If you’ve been thinking about coming, now’s the time to book your place www.alkpositive.org.uk/national-con... #LCSM

051

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 25/08/2026

What an amazing job Jade has done 🤩 She was understandably nervous about doing a syndicated interview, but went for it, & stayed focused on what she wanted to say about her experience of living with stage 4 ALK+ #lungcancer. Now her story has gone global even appearing in the New York Post. #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 20/08/2026

🆕 study has found children’s lungs grew bigger & worked better after ULEZ. Outdoor air pollution & particulate matter are classified by IARC as carcinogenic with sufficient evidence that they cause #lungcancer. So this is a significant real-world example of what cleaner air can mean for lungs.

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 13/08/2026

What could come next for ALK+ #lungcancer treatment? At our 2025 National Conference, Prof Sanjay Popat looked at next-generation ALK inhibitors, ADCs, PROTACs & molecular glues. He also features on the programme for our 5th Conference 25-27 September. www.alkpositive.org.uk/national-con... #LCSM

040

Reposted by ALK Positive Lung Cancer UK

The King's Fund @thekingsfund.bsky.social · 12/08/2026

This International Youth Day, we’re celebrating the power of young people’s voices. Through our work with young people, one thing is clear: they want their voices heard. Interested to hear what they have to say? Our upcoming event is co-produced with young people themselves: bit.ly/4vv2msm

Four people stand in a circle, hands together in the center, participating in a group activity. Two individuals wear black shirts with Barnardo's logos and name tags. A sign nearby displays Barnardo's, noting a partnership. A presentation screen with partially visible text is in the background.

A group of people seated in a conference room, wearing lanyards. One person is holding a small colorful ball and appears to be speaking or asking a question. The background shows blurred figures and framed items on the wall.

022

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 08/08/2026

A 🆕 study published in JTO (Kamali et al., 2026) found that > 1/3 people living with ALK+ #lungcancer develop blood clots during their illness, often well into treatment, not just at diagnosis. Blood clots are treatable when caught early. Don’t wait for symptoms to start the conversation. #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 07/08/2026

When ALK+ #lungcancer progresses, there can be a lot to take in & important decisions to discuss. Our 🆕 Talking Points resource is designed to support those conversations, with practical questions people may want to discuss with their healthcare team. www.alkpositive.org.uk/our-publicat... #LCSM

050

Reposted by ALK Positive Lung Cancer UK

The Francis Crick Institute @crick.ac.uk · 28/07/2026

Our clinical director Charlie Swanton spoke to James Gallagher on Inside Health this morning about his team's work investigating the biological processes that link inflammation and lung cancer. Catch up on BBC Sounds from 5:35 www.bbc.co.uk/sounds/play/m002zggr

bbc.co.uk

Inside Health - Is inflammation behind all chronic disease? - BBC Sounds

How understanding inflammation could transform treatments from cancer to Alzheimer’s.

041

Reposted by ALK Positive Lung Cancer UK

Respro® Masks @resprouk.bsky.social · 07/08/2026

Why Britain is breathing the world’s wildfire smoke Scientists say global blazes account for 10% of UK’s particle pollution – and climate crisis could make the problem worse #AirPollution #Wildfires #WildfireSmoke www.theguardian.com/environment/... by @drgaryfuller.bsky.social

theguardian.com

Why Britain is breathing the world’s wildfire smoke

Scientists say global blazes account for 10% of UK’s particle pollution – and climate crisis could make the problem worse

044

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 05/08/2026

Wales’ new 10-yr cancer strategy must recognise that #lungcancer is not one disease. For people with ALK+, that means faster diagnosis, comprehensive biomarker testing, equal access to specialist care & targeted treatments, & research into drug resistance & brain mets. #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 04/08/2026

What draws an oncologist to work in ALK+ #lungcancer? Dr Tom Newsom-Davis, who is the keynote speaker for our 5th National Conference this September shares his thoughts. He speaks about the impact of seeing people do well - often year after year, & how incredibly rewarding that is. #LCSM

150

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 02/08/2026

19 yrs ago today, a Japanese research team led by Dr Hiroyuki Mano published the 1st paper describing the ALK rearrangement in #lungcancer. That discovery changed the future of ALK+, paving the way for targeted treatments that have transformed care & helped many people live longer & better. #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 01/08/2026

1 August is #WorldLungCancerDay. Imagine being 28, a cough that won’t go, & you’ve never smoked. Nobody investigates & by the time it’s found it’s stage 4. 65% of people with #lungcancer delay seeking help*, often due to age or smoking status. Push for answers. *Source: Lung Cancer Europe #LCSM

060

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 25/07/2026

Changes in mood, thinking and behaviour associated with ALK+ #lungcancer inhibitors, particularly lorlatinib, remain an important aspect of treatment that deserves greater awareness. Our website Treatments section provides an overview of the available ALK inhibitors and practical resources. #LCSM

140

Reposted by ALK Positive Lung Cancer UK

The King's Fund @thekingsfund.bsky.social · 22/07/2026

Current ambitions to improve health and reduce inequalities risk falling short if we continue to overlook the role of preconception health. Veena Raleigh explores why improving preconception health must become a much bigger public health priority. Read the blog: bit.ly/4yF4gtt

012

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 18/07/2026

8 yrs ago we had our 1st meet-up which was the start of ALK+ #LungCancer UK’s journey! 💙 In 2018, with no ALK+ UK support groups, Debra, our Chair, reached out to fellow UK patients on a US forum. There were 18 at the meet-up & we were incredibly fortunate to have Prof Sanjay Popat join us. #LCSM

050

Reposted by ALK Positive Lung Cancer UK

Lung Cancer Europe @lungcancereurope.bsky.social · 16/07/2026

Which is the world’s biggest cancer killer? The latest WHO Global Status Report on Cancer shows lung cancer remained the leading cause of cancer death worldwide in 2024. Read our 9 key takeaways. 🔗 lungcancereurope.eu/news/9-takea... #LungCancer #LCSM

041

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 09/07/2026

New in NEJM: The Phase III ELEVATE trial found that adjuvant ensartinib significantly improved disease-free survival after surgery for ALK-positive #lungcancer. Another reminder that biomarker testing is increasingly important in early-stage lung cancer too. www.nejm.org/doi/full/10.... #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 09/07/2026

New from ALK+ UK: Talking Points - a practical guide to help people with ALK-positive #lungcancer prepare for conversations with their healthcare team. It also carries the PIF TICK for trusted health information. Read and download 🔗 tr.ee/sfj70T0tHU #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 08/07/2026

The Brenda Cobb Hardship Fund offers grants of up to £500 to help people affected by ALK+ #lungcancer facing financial hardship. It can also help with private NGS in some cases. A sincere 🙏 to Brenda’s som Callum for creating this fund Find out more: www.alkpositive.org.uk/hardship-fun... #LCSM

040

Reposted by ALK Positive Lung Cancer UK

The King's Fund @thekingsfund.bsky.social · 07/07/2026

'England lost public health from the NHS in 2013 through misjudgement and poor specification. The next generation of NHS architecture is being designed now. We don't have to make the same mistake again.' Guest blog authors, Joe Home, Joe Dallaz and Frances Burnett Read more: bit.ly/3SQPjnu

Blog post titled "The mistake we don't have to repeat from the 2013 NHS reforms" by Joe Home, Joe Dalloz, and Frances Burnett from The King's Fund.

021

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 07/07/2026

Researchers at the University of Glasgow have launched the SWIFT-Lung study to investigate whether AI could help identify lung nodules more quickly and consistently. The technology is designed to support clinical teams, with the aim of improving #lungcancer diagnosis and patient care. #LCSM

040

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 06/07/2026

Prof Alastair Greystoke, Thoracic Consultant at Newcastle Cancer Centre, is our new Honorary Clinical Advisor. Here he talks through the developments he is watching closely in ALK+ #lungcancer: new tablets, new drug classes, and approaches that use the immune system in more targeted ways. #LCSM

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 18/06/2026

Our new guide, Talking Points, has been created to help people with ALK+ #lungcancer ask useful questions during appointments with their healthcare team. It covers treatment decisions, QOL, scans, ECGs, bone mets, blood clots, side effects, supportive, palliative care, & more! #LCSM

171

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 13/06/2026

Leptomeningeal disease is an uncommon but serious problem in ALK+ #lungcancer. At #ASCO26, the largest study found people given lorlatinib after diagnosis lived far longer than those on a 2nd-gen TKI like alectinib or brigatinib (32.6 vs 7 months). Retrospective, no UK data. shorturl.at/nVw1V #LCSM

050

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 10/06/2026

This week is Carers Week (8-14 June). 1 in 4 #lungcancer carers in the UK rarely or never talk about how they’re feeling. That’s one of the findings from a Lung Cancer Europe survey that our community took part in. Supporting someone you love through a lung cancer diagnosis is hard. #LCSM

040

Reposted by ALK Positive Lung Cancer UK

Critical Care Reviews @criticalcarereviews.com · 10/06/2026

#CCR26 begins! 3 days of practice-changing clinical trial results, all from sunny Belfast! Join us at the foot of the famous titanic steps, or online at criticalcarereviews.com

criticalcarereviews.com

Home

The most up-to-date critical care website in the world

033

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 04/06/2026

🙌 It’s Volunteers’ Week and we want to say a big thank you to everyone who gives their time so generously to volunteer for ALK+ UK and help us better support our ALK+ #lungcancer community. If would like to help us or just find out more, email hello@alkpositive.org.uk. #LCSM

061

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 01/06/2026

New at #ASCO26: the LORIN trial tested lorlatinib before surgery in stage III ALK+ #lungcancer. 75% of those initially considered inoperable went on to have surgery. pCR 47%, MPR 81%, 1-year EFS 97%. Early data, but notable results. #LCSM ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.8002

040

Reposted by ALK Positive Lung Cancer UK

JCO Journals @jco-asco.bsky.social · 30/05/2026

‼️ #ASCO26 simultaneous publication by Trosman et al: Optimizing Cancer Care Delivery Through High-Functioning Teams: Results of Implementing the 4R Oncology Model in Lung and Breast Cancer Read the full article: bit.ly/4v6hwoa #lcsm #bcsm

021

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 28/05/2026

After lorlatinib, what comes next for ALK+ #lungcancer? New ASCO 2026 data on neladalkib - the Nuvalent trial - shows 31% response in heavily pre-treated patients, rising to 46% without prior lorlatinib. Early data, not yet approved. But a real signal. Abstract 8503 #ASCO26 #LCSM

182

Reposted by ALK Positive Lung Cancer UK

Hidehito HORINOUCHI @hhorinouchi.bsky.social · 28/05/2026

🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1 🆙 @JCO_ASCO ☑Latest update incorporating new evidence for ICI-based regimens in NSCLC 🎙Dr. Lyudmila Bazhenova @hhorinouchi.bsky.social #LCSM @oncoalert.bsky.social @ascocancer.bsky.social doi.org/10.1200/JCO-...

072

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 25/05/2026

Great news. 10K+ #lungcancer cases now detected by NHS mobile scanning units in England - 75% at stage 1 or 2, when survival rates are nearly 13X higher. This programme targets those with smoking history aged 55-74. In our ALK+ UK community, 73% never smoked and 1/2 are < 50 at diagnosis. #LCSM

051

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 25/05/2026

Understanding the needs and experiences of our ALK+ #lungcancer community helps us to better support and advocate for them. Treatment challenges are a big part of that reality. Different treatments bring different challenges - and this data helps us make sure those challenges are heard. #LCSM

050

Reposted by ALK Positive Lung Cancer UK

EACR - European Association for Cancer Research @helloeacr.bsky.social · 25/05/2026

Discover exciting new publications in the latest edition of Highlights in Cancer Research! Our Highlights in Cancer Research is a summary of the most interesting & impactful papers in cancer research, curated by the EACR Board. Read more in The Cancer Researcher: magazine.eacr.org/highlights-i...

053

Reposted by ALK Positive Lung Cancer UK

Royal College of Nursing @rcn.org.uk · 25/05/2026

Health alerts have been issued as we're set to see sustained high temperatures in parts of the UK over the coming days. ⚠️☀️ Employers have a duty of care to keep you safe in hot weather. Know your rights and how to stay safe in the heat: bit.ly/4wJyV7P

rcn.org.uk

Working in the heat: know your rights | RCN Magazine | Royal College of Nursing

Unforgiving uniforms, outdated heating systems and lack of water stations can create dangerous work environments. Employers have a duty of care to keep you safe in hot weather

085

ALK Positive Lung Cancer UK @alkpositiveuk.bsky.social · 23/05/2026

At 7 years, 44% of people with ALK+ #lungcancer on lorlatinib in the CROWN trial are still on treatment. This remarkable data will be presented at ASCO 2026 in Chicago next week. After 7 years of follow-up, the median progression-free survival with lorlatinib has still not been reached. #LCSM

040